These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25967144)

  • 21. Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
    Podaza E; Carri I; Aris M; von Euw E; Bravo AI; Blanco P; Ortiz Wilczyñski JM; Koile D; Yankilevich P; Nielsen M; Mordoh J; Barrio MM
    Front Immunol; 2020; 11():1147. PubMed ID: 32582212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
    De Keersmaecker B; Claerhout S; Carrasco J; Bar I; Corthals J; Wilgenhof S; Neyns B; Thielemans K
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.
    Ressing ME; van Driel WJ; Brandt RM; Kenter GG; de Jong JH; Bauknecht T; Fleuren GJ; Hoogerhout P; Offringa R; Sette A; Celis E; Grey H; Trimbos BJ; Kast WM; Melief CJ
    J Immunother; 2000; 23(2):255-66. PubMed ID: 10746552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
    Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
    Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells.
    Schuler-Thurner B; Dieckmann D; Keikavoussi P; Bender A; Maczek C; Jonuleit H; Röder C; Haendle I; Leisgang W; Dunbar R; Cerundolo V; von Den Driesch P; Knop J; Bröcker EB; Enk A; Kämpgen E; Schuler G
    J Immunol; 2000 Sep; 165(6):3492-6. PubMed ID: 10975870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination.
    Vence LM; Wang C; Pappu H; Anson RE; Patel TA; Miller P; Bassett R; Lizee G; Overwijk WW; Komanduri K; Benjamin C; Alvarado G; Patel SP; Kim K; Papadopoulos NE; Bedikian AY; Homsi J; Hwu WJ; Boyd R; Radvanyi L; Hwu P
    J Immunother; 2013 May; 36(4):276-86. PubMed ID: 23603862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program.
    Cochlovius B; Stassar M; Christ O; Raddrizzani L; Hammer J; Mytilineos I; Zöller M
    J Immunol; 2000 Oct; 165(8):4731-41. PubMed ID: 11035118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
    Dangoor A; Lorigan P; Keilholz U; Schadendorf D; Harris A; Ottensmeier C; Smyth J; Hoffmann K; Anderson R; Cripps M; Schneider J; Hawkins R
    Cancer Immunol Immunother; 2010 Jun; 59(6):863-73. PubMed ID: 20043222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Requirement of tumor-associated antigen-specific CD4+ T cells for an efficient dendritic cell vaccine in antitumor immunotherapy.
    Simon T; Fonteneau JF; Grégoire M
    Immunotherapy; 2013 Jun; 5(6):565-7. PubMed ID: 23725279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax.
    Mansour M; Pohajdak B; Kast WM; Fuentes-Ortega A; Korets-Smith E; Weir GM; Brown RG; Daftarian P
    J Transl Med; 2007 Apr; 5():20. PubMed ID: 17451606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment of HLA-DR4 transgenic mice for the identification of CD4+ T cell epitopes of tumor-associated antigens.
    Yatsuda J; Irie A; Harada K; Michibata Y; Tsukamoto H; Senju S; Tomita Y; Yuno A; Hirayama M; Abu Sayem M; Takeda N; Shibuya I; Sogo S; Fujiki F; Sugiyama H; Eto M; Nishimura Y
    PLoS One; 2013; 8(12):e84908. PubMed ID: 24386437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of CD4+ T cell epitopes in C. burnetii antigens targeted by antibody responses.
    Chen C; Dow C; Wang P; Sidney J; Read A; Harmsen A; Samuel JE; Peters B
    PLoS One; 2011 Mar; 6(3):e17712. PubMed ID: 21423609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.
    Smithers M; O'Connell K; MacFadyen S; Chambers M; Greenwood K; Boyce A; Abdul-Jabbar I; Barker K; Grimmett K; Walpole E; Thomas R
    Cancer Immunol Immunother; 2003 Jan; 52(1):41-52. PubMed ID: 12536239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
    Davila E; Celis E
    J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.
    Becker JC; Andersen MH; Hofmeister-Müller V; Wobser M; Frey L; Sandig C; Walter S; Singh-Jasuja H; Kämpgen E; Opitz A; Zapatka M; Bröcker EB; Thor Straten P; Schrama D; Ugurel S
    Cancer Immunol Immunother; 2012 Nov; 61(11):2091-103. PubMed ID: 22565484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.